Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial
Catherine C. Smith(University of California, San Francisco), Erkut Bahceci(Astellas Pharma (United States)), Wen‐Chien Chou(National Taiwan University), Christian Récher(Institut universitaire du cancer de Toulouse Oncopole), Alexander E. Perl(University of Pennsylvania), Andreas Neubauer(RWTH Aachen University), Maria R. Baer(University of Maryland, Baltimore), Jason E. Hill(Essen BioScience (United States)), Richard A. Larson(Urbana University), Giovanni Martinelli(University of Bologna), Mark J. Levis(Sidney Kimmel Cancer Center), Hisayuki Yokoyama(Sendai Medical Center), Sung‐Soo Yoon(Seoul National University Hospital), Ellin Berman(Memorial Sloan Kettering Cancer Center), Matt Rosales(Astellas Pharma (United States)), Pau Montesinos(Instituto de Salud Carlos III)
Cited by 25
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k